Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series

October 2024 in “ Clinical Cosmetic and Investigational Dermatology ”

Enrico Matteini, Laura Diluvio, Sara Lambiase, Arnaldo Cioni, Ruslana Gaeta Shumak, Gaetana Costanza, Caterina Lanna, Giacomo Caldarola, Luca Bianchi, Elena Campione

This case series explores the use of Brevilin-A, a natural JAK inhibitor, as a treatment for pediatric alopecia areata. Brevilin-A, derived from Centipeda minima, works by inhibiting the JAKs tyrosine kinase domain JH1 and blocking STAT3 and STAT1 signaling. The study reports successful outcomes in pediatric patients, indicating that Brevilin-A is a safe and effective treatment option for mild to moderate alopecia areata in children and adolescents, including cases that are resistant to other treatments.

View this study on dovepress.com →

Discuss this study in the Community →

Research cited in this study

8 / 8 results

research Quality of life in children and adolescents with alopecia areata—A systematic review

39 citations , January 2023 in “Journal of the European Academy of Dermatology and Venereology”

Impact of Pediatric Alopecia Areata on Quality of Life of Patients and Their Family Members: A Nationwide Multicenter Questionnaire Study

research Impact of Pediatric Alopecia Areata on Quality of Life of Patients and Their Family Members: A Nationwide Multicenter Questionnaire Study

17 citations , January 2022 in “Annals of Dermatology”

Severe pediatric alopecia areata worsens quality of life for patients and families.

research Treatment of Pediatric Alopecia Areata: A Systematic Review

48 citations , April 2021 in “Journal of the American Academy of Dermatology”

Topical corticosteroids are the best initial treatment for children's alopecia areata.

research Hair Growth Effect of Emulsion Extracted Brevilin A, a JAK3 Inhibitor, from Centipeda Minima

15 citations , June 2020 in “Processes”

CMX from Centipeda minima can significantly improve hair growth in mild to moderate balding.

research Alopecia Areata: A Long-Term Follow-Up Study of 104 Patients

29 citations , March 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

Older age at onset of alopecia areata leads to less severe and shorter episodes, with most patients experiencing significant hair regrowth.

research JAK Inhibitors for Treatment of Alopecia Areata

63 citations , July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology”

JAK inhibitors can effectively reverse hair loss in people with alopecia areata.

research Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata

83 citations , June 2017 in “Journal of the American Academy of Dermatology”

Topical JAK inhibitors may help children with alopecia areata regrow hair.

research Clobetasol Propionate, 0.05%, vs Hydrocortisone, 1%, for Alopecia Areata in Children

49 citations , November 2013 in “JAMA dermatology”

Clobetasol propionate, 0.05%, is more effective and safe for treating childhood alopecia areata than hydrocortisone, 1%.

Related Research

1 / 1 results

research Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child

April 2019 in “International journal of research in dermatology”

A child with rough nails also had hair loss and allergies.